Annual Results – Appendix 4E

"The CLINUVEL team has delivered what it set out to achieve in FY2025: continued commercial growth while accelerating our Phase III clinical program for vitiligo in a cost-controlled manner. This year’s result sees us deliver a ninth year of profits from the commercial distribution of SCENESSE® for EPP.

All of our key financial metrics - revenue, profit , re-investment in the business and assets growth - continue to increase year-on-year, providing a strong basis for a bio-pharmaceutical group and enabling us to expedite our objectives for the revenues and growth of tomorrow"

Peter Vaughan, Chief Financial Officer